Zim Laboratories Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Revenue growth with margin lag: Total operating income rose 7.4% YoY to ₹92.2 crore, but PAT margin compressed to 1.9% as depreciation, finance costs and R&D investment ran ahead of revenue realization.
• The NIP/OTF pivot is gaining weight: These segments plus licensing fees reached 21.6% of H1 revenue, up from 14% a year ago, driven by registrations from filings made three to four years ago.
• First EU approval unlocks the regulated-market story: The Azithromycin Oral Suspension marketing authorization is the first tangible proof that the NIP strategy can deliver in developed markets, though commercialization is just beginning.
• Expenses are front-running revenue by design: Capacity build-out, validation batches, regulatory teams and interest on the new facility are all hitting the P&L now; management expects the revenue those investments support to materialize from FY26 onward.
• What to watch next quarter: Whether the sublingual film and one NIP product in final submission stages secure approvals, any firmer OTF revenue outlook, and the pace of licensing-fee milestone collection in H2.

The NIP & OTF Build-Out

• NIP pipeline nearing completion: Six of the initial 10 NIP products have been developed and filed; the remaining four are targeted for completion and filing in Q4 FY25 or Q1 FY26.
• Filings are stacking up in developed markets: Seven NIP filings were completed in the EU and one in Australia during H1 FY25, alongside one OTF filing in each of those markets.
• First EU win de-risks the thesis: The Azithromycin Oral Suspension MA validates that ZIM's dossiers, facilities and IP can pass a developed-market regulatory review, and commercialization efforts have now commenced.
• Revenue impact is a FY26 story: Management stated explicitly that nonlinear growth from regulated markets will begin in FY26, once a portfolio of products with marketing authorization is established, roughly six to seven months after receiving each MA.
• Sublingual film could be a door-opener: A sublingual oral film is in the final stages of approval; management believes it will demonstrate technology versatility and open doors for the company.

Dr. Anwar S. Daud: "Once this product is in the market after the MA, which we hopefully expect to receive soon, perhaps that would open many doors for the ZIM Laboratories."

Partnership Model & Commercialization

• Partners are chosen per product, per market: For each NIP product, ZIM has selected a partner strong in that therapy area and geography, with rigorous due diligence conducted on dossiers, facilities, skills and competence.
• Agreements are non-exclusive: Almost all agreements leave scope for ZIM to also play in the same market, preserving optionality.
• Outlicensing fees are flowing: Licensing fees are being received in line with agreements, and management expects a little more in H2 because some milestones are coming up.
• Marketing push is still being built: The company has recruited and strengthened its marketing team for emerging markets and RoW this year, but marketing for regulated markets has yet to start; that is a B2B play that begins once MAs are in hand.
• Partner validation reinforces confidence: Management cited agreements from well-established European players who have completed due diligence as evidence that the product quality and IP are real.

Dr. Anwar S. Daud: "For each product, we have chosen a partner who is strong in that therapy area and who is strong in his own market, who understands the market well because if you see ZIM for wealth and for most people in the regulated markets, most clients in the regulated markets, ZIM is a new entrant."

Revenue & Seasonality Dynamics

• Exports are the dominant engine: Exports contributed 84% of total H1 revenue (₹146.7 crore), up from 79.4% in the same period last year, driven by ROW registrations converting filings into orders.
• Pharma leads, nutra holds steady: The pharmaceutical segment contributed 69% of H1 revenue, nutraceutical 31%.
• H2 is structurally heavier: Historically H1 contributes 40-45% of full-year revenue and H2 55-60%, a pattern driven by institutional domestic business and Pharmerging/RoW import permissions that arrive from January onward.
• Seasonality should smooth over time: Management expects the H1/H2 skew to level out in the medium run as regulated-market business and new products change the mix.
• OTF is an emerging wildcard: The OTF segment grew to 4.9% of Q2 revenue and is seeing an interesting upsurge, but management reserved a firmer view until the end of next quarter, citing agreements and orders still being executed.

Dr. Anwar S. Daud: "Traditionally the Company has 55% or 60% of the business in the second half. We're just giving you something, which is a guideline and this is what the Company has normally done. I also said that as the Company's regulated market business and different products that it is introducing actually start yielding return, we expect that this kind of staggering would actually level out in the long run or in the medium run."

Profitability & Cost Structure

• PAT margin compressed to 1.9%: Increased depreciation and finance costs absorbed the benefit of revenue growth at the net-profit level in H1 FY25.
• R&D spend is rising and partly capitalized: R&D investment reached 9.7% of H1 revenue, up from 8.7%. Bioequivalence studies and product registration costs are capitalized as intangible assets under development and amortized over three years once an MA is received; regular R&D expenses flow through the P&L.
• Expense build-up is deliberate: All costs related to product development, capacity building, process validation batches, facility validation and the regulatory team for European/regulated markets are being debited now, alongside CAPEX and filings. Interest cost rose due to the term loan and the new facility under construction.
• Capacity utilization is low but intentional: Utilization remains sub-40% against an optimum of up to 60%, reflecting capacity built ahead of expected demand.
• Raw material pass-through is working: For most agreements, the company can pass increased raw material costs to clients. Currency-related headwinds are easing but have not eased as much as expected due to the geopolitical situation.

Balance Sheet & Capital Allocation

• CAPEX is on track: FY25 capital expenditure remains focused on completing the NIP urology suite and capacity expansion for key nutraceutical and OTC products.
• CWIP to capitalize by year-end: Projects are expected to be completed by year-end, with most CWIP targeted for capitalization in March 2025.
• Debt repayment is steady: The company normally repays bankers to the extent of ₹15 to 18 crore annually.
• No near-term equity raise: Gearing is sufficient at around 40%, and there are no plans for further equity infusion or liquidation. Triggers for future fundraising exist (a new highly regulated territory, a sudden influx of business) but none are active in the near future.
• Working capital is healthy: The working capital cycle has improved from FY24, and the healthy trend is expected to continue.

Guidance & Commitments

Key Metrics